Skip to main content
Editas Medicine, Inc. logo

Editas Medicine, Inc. — Investor Relations & Filings

Ticker · EDIT ISIN · US28106W1036 LEI · 5299000AON4Q9NT2JE42 US Professional, scientific and technical activities
Open in API
Filings indexed 679 across all filing types
Latest filing 2019-09-13 Director's Dealing
Country US United States of America
Listing US EDIT

About Editas Medicine, Inc.

https://www.editasmedicine.com/

Editas Medicine, Inc. is a clinical-stage genome editing company focused on developing transformative medicines for serious diseases using CRISPR technology. The company's mission is to discover, develop, and commercialize durable, precision genomic therapies that can correct the underlying genetic causes of various conditions. Its proprietary platform enables the precise revision, removal, or replacement of DNA. Editas Medicine's research and development pipeline is concentrated on creating both in vivo (in-body) and ex vivo (out-of-body) gene-edited medicines to treat a broad class of diseases, with a focus on rare genetic disorders.

Recent filings

Filing Released Lang Actions
FORM 4 -
Director's Dealing
2019-09-13 English
FORM 4 -
Director's Dealing
2019-08-21 English
FORM 4 -
Director's Dealing
2019-08-07 English
10-Q
Interim / Quarterly Report Q2 2019
2019-08-07 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 6, 2019, reporting the issuance of a press release announcing financial results for the fiscal quarter ended June 30, 2019. The text explicitly states that the press release is furnished as an exhibit and is not filed as part of the report. The document length is 3640 characters, which is relatively short and consistent with an 8-K filing announcing earnings results rather than the full earnings release itself. The document does not contain detailed financial statements or substantive financial data but rather references the press release. According to the classification rules, an initial announcement of quarterly financial results in a press release format corresponds to an Earnings Release (ER). Although this is an 8-K filing, the content is the earnings release announcement. Therefore, the correct classification is Earnings Release (ER).
2019-08-06 English
FORM 4 -
Director's Dealing
2019-06-14 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.